• 1
    Gherardi E,Sharpe M,Lane K,Sirulnik A,Stoker M. Hepatocyte growth factor/scatter factor (HGF/SF), the c-Met receptor and the behavior of epithelial cells. Symp Soc Exp Biol. 1993; 47: 163181.
  • 2
    Rubin J,Bottaro D,Aaronson S. Hepatocyte growth factor/scatter factor and its receptor, the c-Met proto-oncogene product. Biochim Biophys Acta. 1993; 1155: 357371.
  • 3
    Weidner K,Hartmann G,Naldini L, et al. Molecular characteristics of HGF-SF and its role in cell motility and invasion. EXS. 1993; 65: 311328.
  • 4
    Zarnegar R. Regulation of HGF and HGFR gene expression. EXS. 1993; 74: 3349.
  • 5
    Stoker M,Gherardi E,Perryman M,Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell motility. Nature. 1987; 327: 239242.
  • 6
    Bussolino F,Di Renzo MF,Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992; 119: 629641.
  • 7
    Michalopoulos GK. Liver regeneration: molecular mechanisms of growth control. FASEB J. 1990; 4: 176187.
  • 8
    Nakamura T,Nishizawa T,Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989; 342: 440443.
  • 9
    Matsumoto K,Tajima H,Nakamura T. Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth. Biochem Biophys Res Commun. 1991; 176: 4551.
  • 10
    Rubin JS,Chan AM,Bottaro DP, et al. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci USA. 1991; 88: 415419.
  • 11
    Kan M,Zhang G,Zarnegar R, et al. Hepatocyte growth factor, hepatopietin-A stimulates the growth of rat kidney proximal tubules epithelial cell (rpte), rat nonparechymal liver cells, human melanoma cells and mouse keratinocytes, and stimulates anchorage independent growth of SV40-transfo. Biochem Biophys Res Commun. 1991; 174: 331337.
  • 12
    Montesano R,Matsumono K,Nakamura T,Orci L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell. 1991; 67: 901908.
  • 13
    Tsarfaty I,Resau JH,Rulong SL,Keydar I,Faletto DL,Vande Woude GF. The met proto-oncogene receptor and lumen formation. Science. 1992; 257: 12581261.
  • 14
    Gherardi E,Gray J,Stoker J,Perryman M,Furlong R. Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. Proc Natl Acad Sci U S A. 1989; 86: 58445848.
  • 15
    Comoglio P. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. EXS. 1993; 65: 130165.
  • 16
    Nakamura S,Gohda E,Matsunaga T,Yamamoto I,Minowada J. Production of hepatocyte growth factor by human haematopoietic cell lines. Cytokine. 1994; 6: 285294.
  • 17
    Di Renzo MF,Narsimhan RP,Oliviero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissue. Oncogene. 1991; 6: 19972003.
  • 18
    Prat M,Narsimham BP,Crepaldi T,Nicotra MR,Natali PG,Comoglio PM. The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer. 1991; 49: 323328.
  • 19
    Sonnenberg E,Meyer D,Weider K,Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol. 1993; 123: 223235.
  • 20
    Park M,Dean M,Cooper C,Schmidt M,O'Brian S,Blair D. Mechanism of met oncogene activation. Cell. 1986; 45: 895904.
  • 21
    Cooper C,Park M,Blair D,Tainsky M,Huebner K,Croce C. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984; 311: 2933.
  • 22
    Rong S,Bodescot M,Blair D,Dunn J,Nakamura T,Mizuno K. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol. 1992; 12: 51525158.
  • 23
    Jin L,Fuchs A,Schnitt SJ, et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer. 1997; 79: 749760.
  • 24
    Kuniyasu H,Yasui W,Kitadai Y,Yokozaki H,Ito H,Tahara E. Frequent amplification of the c-met gene in scirrhous-type stomach cancer. Biochem Biophys Res Commun. 1992; 189: 227232.
  • 25
    Pisters L,Troncoso P,Zhau H,Li W,Eschenbach A,Chung L. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol. 1995; 154: 293298.
  • 26
    Grigioni W,Fiorentino M,D'Errico A,Ponzetto A,Crepaldi T,Prat M. Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. Hepatology. 1995; 21: 15431546.
  • 27
    Oda Y,Sakamoto A,Saito T,Kinukawa N,Iwamoto Y,Tsuneyoshi M. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol. 2000; 31: 185192.
  • 28
    Ferracini R,Di Renzo MF,Scotlandi K, et al. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either paracrine or an autocrine circuit. Oncogene. 1995; 10: 739749.
  • 29
    Rong S,Jeffers M,Resau JH,Tsarfaty I,Oskarsson M,Vande Woude GF. Met expression and sarcoma tumorigenicity. Cancer Res. 1993; 53: 53555360.
  • 30
    Scotlandi K,Baldini N,Oliviero M, et al. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol. 1996; 149: 12091219.
  • 31
    Ruco LP,Ranalli T,Marzullo A, et al. Expression of Met protein in thyroid tumours. J Pathol. 1996; 180: 266270.
  • 32
    Terada T,Nakanuma Y,Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998; 29: 175180.
  • 33
    Nakapoulou L,Gakiopoulou H,Keramopoulos A, et al. c-met tyrosine kinase receptor expression is associated with abnormal beta-catenin expression and favourable prognostic factors in invasive breast carcinoma. Histopathology. 2000; 36: 313325.
  • 34
    Aishima SI,Taguchi KI,Sugimachi K, et al. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology. 2002; 40: 269278.
  • 35
    Furukawa T,Duguid WP,Kobari M,Matsuno S,Tsao MS. Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol. 1995; 147: 889895.
  • 36
    Naka T,Iwamoto Y,Shinohara N,Ushijima M,Chuman H,Tsuneyoshi M. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors. Mod Pathol. 1997; 10: 832838.
  • 37
    Weinberger PM,Yu Z,Kowalski D, et al. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chrodoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg. 2005; 131: 707711.
  • 38
    O'Connell JX,Renard LG,Liebsch NJ,Efird JT,Munzerider JE,Rosenberg A. Base of skull chordoma: a correlative study of histologic and clinical features of 62 cases. Cancer. 1994; 74: 22612267.
  • 39
    Volpe R,Mazabraud A. A clinicopathologic review of 25 cases of chordoma: a pleomorphic and metastasizing neoplasm. Am J Surg Pathol. 1983; 7: 161170.
  • 40
    Bergh P,Kindblom L,Gunterberg B,Remotti F,Ryd W,Meis-Kindblom J. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000; 88: 21222134.
  • 41
    Naka T,Boltze C,Kuester D, et al. Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B and urokinase plasminogen activator in non-skull base chordoma. Am J Clin Pathol. 2004; 122: 926930.
  • 42
    Naka T,Boltze C,Samii S, et al. Skull base and non-skull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability. Cancer. 2003; 98: 19341941.
  • 43
    Naka T,Boltze C,Kuester D, et al. Intralesional fibrous septum in chordoma: a clinicopathologic and immunohistochemical analysis in 122 lesions. Am J Clin Pathol. 2005; 124: 288294.
  • 44
    Kumaki F,Matsui K,Kawai T, et al. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol. 2001; 159: 21252135.
  • 45
    Naka T,Kuester D,Boltze C, et al. Expression of matrix metalloproteinases-1, -2, -9, tissue inhibitors of matrix metalloproteinases-1, -2, cathepsin B, urokinase plasminogen activator and plasminogen activator inhibitor-1 in skull base chordoma. Hum Pathol. In press.
  • 46
    Naka T,Boltze C,Kuester D, et al. Alterations of G1-S checkpoint in chordoma: prognostic impact of p53 overexpression. Cancer. 2005; 104: 12551263.
  • 47
    Belfiore A,Gangemi P,Costantino A, et al. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab. 2006; 82: 23222328.
  • 48
    Scheil S,Bruederlein S,Liehr T, et al. Genome wide analysis of 16 chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosom Cancer. 2001; 32: 203211.
  • 49
    Brandal P,Bjerkehagen B,Danielsen H,Heim S. Chromosome 7 abnormalities are common in chordomas. Cancer Genet Cytogenet. 2005; 160: 1521.
  • 50
    Sawyer JR,Husain M,Al-Mefty O. Identification of isochromosome 1q as a recurring chromosome aberration in skull base chordomas: a new marker for aggressive tumors? Neurosurg Focus. 2001; 10: 16.
  • 51
    Naka T,Iwamoto Y,Shinohara N,Chuman H,Fukui M,Tsuneyoshi M. Cytokeratin subtyping in chordomas and fetal notochord: an immunohistochemical analysis of aberrant expression. Mod Pathol. 1997; 10: 545551.